Jose Malagon‐Rangel

Jose Malagon‐Rangel

Auto-generated profile, based on publicly available information

Jose Malagon‐Rangel

Internal Medicine Department, Hospital de Especialidades, Centro Médico Nacional Siglo XXI Instituto Mexicano del Seguro Social Mexico City Mexico

Research Focus & Metrics

Academic Career Length

22Years (2005-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2014 in World Journal of Gastroenterology
Verified
Journal Article
Open access
CLCarlos Alberto García López
Carlos Alberto García López
FLFernando Laredo-Sánchez
Fernando Laredo-Sánchez
JMJosé Malagón-Rangel
José Malagón-Rangel
MFMiguel G Flores-Padilla
Miguel G Flores-Padilla
HNHaiko Nellen-Hummel
Haiko Nellen-Hummel
Intestinal pseudo-obstruction secondary to systemic lupus erythematosus (SLE) is a rare syndrome described in recent decades. There are slightly over 30 published cases in the English language literature, primarily associated with renal and hematological disease activity. Its presentation and evolution are a diagnostic challenge for the clinician. We present four cases of intestinal pseudo-obstruction due to lupus in young Mexican females. One patient had a previous diagnosis of SLE and all presented with a urinary tract infection of varying degrees of severity during their evolution. We consider that recognition of the disease is of vital importance because it allows for establishing appropriate management, leading to a better prognosis and avoiding unnecessary surgery and complications.

1 November 2005 in Annals of Internal Medicine
Verified
Journal Article
Closed access
PDF file
JCJose Halabe Cherem
Jose Halabe Cherem
JMJose Malagon
Jose Malagon
HNHaiko Nellen
Haiko Nellen

1 November 2015 in Archives of Medical Research
Verified
Journal Article
Open access
LALourdes Andrea Arriaga-Pizano
Lourdes Andrea Arriaga-Pizano
EFEduardo Ferat-Osorio
Eduardo Ferat-Osorio
GRGabriela Rodríguez-Abrego
Gabriela Rodríguez-Abrego
IMIsmael Mancilla-Herrera
Ismael Mancilla-Herrera
EDEsteban Domínguez-Cerezo
Esteban Domínguez-Cerezo
CLConstantino López-Macías
Constantino López-Macías
Severe influenza A(H1N1)pdm2009 virus infection cases are characterized by sustained immune activation during influenza pandemics. Seasonal flu data suggest that immune mediators could be modified by wave-related changes. Our aim was to determine the behavior of soluble and cell-related mediators in two waves at the epicenter of the 2009 influenza pandemic. Leukocyte surface activation markers were studied in serum from peripheral blood samples, collected from the 1(st) (April-May, 2009) and 2(nd) (October 2009-February 2010) pandemic waves. Patients with confirmed influenza A(H1N1)pdm2009 virus infection (H1N1), influenza-like illness (ILI) or healthy donors (H) were analyzed. Serum IL-6, IL-4 and IL-10 levels were elevated in H1N1 patients from the 2(nd) pandemic wave. Additionally, the frequency of helper and cytotoxic T cells was reduced during the 1(st) wave, whereas CD69 expression in helper T cells was increased in the 2(nd) wave for both H1N1 and ILI patients. In contrast, CD62L expression in granulocytes from the ILI group was increased in both waves but in monocytes only in the 2(nd) wave. Triggering Receptor Expressed on Myeloid cells (TREM)-1 expression was elevated only in H1N1 patients at the 1(st) wave. Our results show that during the 2009 influenza pandemic a T cell activation phenotype is observed in a wave-dependent fashion, with an expanded activation in the 2(nd) wave, compared to the 1(st) wave. Conversely, granulocyte and monocyte activation is infection-dependent. This evidence collected at the pandemic epicenter in 2009 could help us understand the differences in the underlying cellular mechanisms that drive the wave-related immune profile behaviors that occur against influenza viruses during pandemics.

1 March 2022 in Case Reports in Infectious Diseases
Verified
Journal Article
Open access
PDF file
KSKaren Aida Ibarra Stone
Karen Aida Ibarra Stone
JSJose Gabriel Solis
Jose Gabriel Solis
EBEnrique Blanco-Lemus
Enrique Blanco-Lemus
JMJose Malagón-Rangel
Jose Malagón-Rangel
GGGuadalupe Gordillo-Pérez
Guadalupe Gordillo-Pérez
Hemophagocytic lymphohistiocytosis (HLH) is characterized by a dysregulated activation of the immune system that causes fever, cytopenias, organomegalies, and hemophagocytosis. There are infectious, neoplastic, rheumatologic, and miscellaneous causes. Rickettsioses are a neglected cause of HLH. We report a confirmed case of an immunocompetent woman in Mexico with postpartum HLH secondary to spotted fever. We did a review of the literature for search of similar cases. The association between these two diseases was found in postmortem studies, unrelated to postpartum. This diagnosis should be considered in all patients with HLH without an evident cause in areas of epidemiological risk.

5 December 2023 in Clinical Case Reports
Verified
Journal Article
Open access
JMJose Malagon‐Rangel
Jose Malagon‐Rangel
JSJose Gabriel Solis
Jose Gabriel Solis
LJLuis Fernando Zavala Jonguitud
Luis Fernando Zavala Jonguitud
MBMartín Roberto Basile‐Alvarez
Martín Roberto Basile‐Alvarez
AMAndrea Malagon‐Liceaga
Andrea Malagon‐Liceaga
Key Clinical Message: Tumor‐induced osteomalacia is a paraneoplastic syndrome characterized by renal phosphate wasting and deranged bone turnover. Clinicians should consider tumor‐induced osteomalacia in unexplained hypophosphatemia and investigate for underlying tumors. Tumor‐induced osteomalacia (TIO) is a rare paraneoplastic syndrome characterized by renal phosphate wasting, which leads to deranged bone turnover. TIO is usually associated with benign mesenchymal tumors, although it has also been reported in malignant tumors. We present the case of a 56‐year‐old individual who experienced a protracted 6‐year clinical course characterized by hypophosphatemia, weakness, and kyphosis, alongside the presence of a foot tumor. Subsequently, this lesion displayed malignant behavior and was ultimately diagnosed as a high‐grade sarcoma. To date, this case is among the 10 reported cases in the literature of a mesenchymal tumor associated with TIO undergoing malignant transformation. This report underscores the importance of a comprehensive evaluation of patients with unexplained hypophosphatemia and highlights the need for diligent follow‐up to detect possible malignant transformation of the underlying tumor. Clinicians should consider TIO in the differential diagnosis of hypophosphatemia and promptly investigate for the presence of an underlying tumor, as early detection may improve the patient's prognosis.

25 October 2023 in Clinical Case Reports
Verified
Journal Article
Open access
JMJose Malagon‐Rangel
Jose Malagon‐Rangel
JSJose Gabriel Solis
Jose Gabriel Solis
LJLuis Fernando Zavala Jonguitud
Luis Fernando Zavala Jonguitud
MBMartín Roberto Basile‐Alvarez
Martín Roberto Basile‐Alvarez
AMAndrea Malagon‐Liceaga
Andrea Malagon‐Liceaga
Key Clinical Message: The detection of a novel HMBS gene mutation (c.457C > T) in a Mexican woman with acute intermittent porphyria underscores the importance of expanding genetic analyses in diverse populations to improve diagnosis, management, and knowledge of the disease's clinical implications. Acute intermittent porphyria (AIP) is an autosomal dominant disorder caused by a deficiency in the enzymatic activity of porphobilinogen deaminase (HMBS), resulting in the accumulation of toxic heme metabolites. In this report, we present the case of a Mexican woman with AIP who experienced recurrent episodes of severe abdominal pain, weakness, vomiting, and insomnia. Despite the challenges in diagnosis and treatment, genetic analysis revealed a novel HMBS mutation, c.457C > T (p.Q153X), located in exon 9. This mutation induces a premature translational stop codon and had not been previously reported in medical literature among individuals with AIP. Remarkably, the patient exhibited a positive response to RNA interference therapy. We hypothesize that this novel HMBS mutation may potentially account for the more severe clinical presentation observed in this case. However, further research is necessary to establish a definitive link between this specific mutation and disease severity. The prevalence and genetic variants of AIP in Mexico remain largely unknown, underscoring the importance of conducting additional research and expanding genetic analyses to gain a better understanding of the clinical implications associated with these mutations.